Dr. Bartizal has over 30 years of anti-infective drug discovery, evaluation and development experience in the pharmaceutical industry. From 2007 to 2013, he served as the Chief Development Officer of Trius Therapeutics, where he led the development of tedizolid phosphate (SIVEXTRO) from pre-IND to NDA filing, until the acquisition of Trius by Cubist Pharmaceuticals, Inc. Prior to joining Trius, Dr. Bartizal was the Executive Director and Head of Infectious Diseases at Merck. While at Merck, Dr. Bartizal contributed to the development of caspofungin acetate (CANCIDAS), the first echinocandin antifungal, from discovery to market. Similarly, he oversaw nonclinical developmental for ertapenem (INVANZ), Merck’s carbapenem antibiotic for antibiotic-resistant bacteria and was a major contributor to IND and NDA filings. At Merck he also brought to Clinical Development an azalide antibiotic gamithromycin (ZACTRAN) for animal health treatment of Bovine Respiratory Disease, and a semisynthetic insecticide for oral treatment of flea and tick infestations in companion animals. Dr. Bartizal started his pharmaceutical career at Pfizer Central Research in Antibiotic Drug Discovery. Dr. Bartizal received his B.S., M.S. and Ph.D. degrees from the University of Notre Dame.